Aislinn Antrim

Community pharmacists are playing an increasing role in sexual and reproductive health services and can provide that trustworthy information to patients. A review of 41 studies found that pharmacists' delivery of sexual and reproductive health services was not only feasible, but it can also improve access for vulnerable and high-risk groups. Patients were also highly receptive to pharmacists' counseling, and interventions were highly accepted and valued. However, researchers noted that integration into daily workflow, policies and regulations, pharmacist reimbursement, and cost for patients are all barriers.

The global temperature has risen by an average of 0.11° Fahrenheit per decade since 1850, or about 2 degrees in total.

The system, currently in early development in Japan, could minimize the need for blood tests, blood pressure cuffs, or expensive wearable devices.

High fluctuations (in the top 25%) in total cholesterol were associated with a 60% increase in dementia and a 23% increase in cognitive decline.

“Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking on its effects on cardiovascular outcomes,” said lead study author Milton Packer, MD, a distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas and a visiting professor at Imperial College in London, in a news release. “This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity.”

Improving collaboration and communication between all members of the health care team is one way to address these challenges.

Within the Veterans Health Administration System, primary care pharmacists are embedded in primary care panels and work alongside primary care physicians and nurses to optimize medication management for patients.

Chronic disease management is incredibly common, but it is associated with high costs and complicated treatment regimens. Value-based payment models are becoming increasingly common, leading clinicians to find novel ways to engage patients and improve disease control with the goal of reducing morbidity, mortality, and cost.

Key Takeaways Inclisiran's twice-yearly dosing improves adherence and reduces LDL-C effectively in ASCVD patients, as shown in ORION trials.

The encouraging results suggest this low-cost, scalable strategy should be considered for population-level outreach globally to improve flu vaccination rates.